TY - JOUR
T1 - Assessment of the upper motor neuron in amyotrophic lateral sclerosis
AU - Huynh, William
AU - Simon, Neil G.
AU - Grosskreutz, Julian
AU - Turner, Martin R.
AU - Vucic, Steve
AU - Kiernan, Matthew C.
N1 - Publisher Copyright:
© 2016 International Federation of Clinical Neurophysiology.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Clinical signs of upper motor neuron (UMN) involvement are an important component in supporting the diagnosis of amyotrophic lateral sclerosis (ALS), but are often not easily appreciated in a limb that is concurrently affected by muscle wasting and lower motor neuron degeneration, particularly in the early symptomatic stages of ALS. Whilst recent criteria have been proposed to facilitate improved detection of lower motor neuron impairment through electrophysiological features that have improved diagnostic sensitivity, assessment of upper motor neuron involvement remains essentially clinical. As a result, there is often a significant diagnostic delay that in turn may impact institution of disease-modifying therapy and access to other optimal patient management. Biomarkers of pathological UMN involvement are also required to ensure patients with suspected ALS have timely access to appropriate therapeutic trials. The present review provides an analysis of current and recently developed assessment techniques, including novel imaging and electrophysiological approaches used to study corticomotoneuronal pathology in ALS.
AB - Clinical signs of upper motor neuron (UMN) involvement are an important component in supporting the diagnosis of amyotrophic lateral sclerosis (ALS), but are often not easily appreciated in a limb that is concurrently affected by muscle wasting and lower motor neuron degeneration, particularly in the early symptomatic stages of ALS. Whilst recent criteria have been proposed to facilitate improved detection of lower motor neuron impairment through electrophysiological features that have improved diagnostic sensitivity, assessment of upper motor neuron involvement remains essentially clinical. As a result, there is often a significant diagnostic delay that in turn may impact institution of disease-modifying therapy and access to other optimal patient management. Biomarkers of pathological UMN involvement are also required to ensure patients with suspected ALS have timely access to appropriate therapeutic trials. The present review provides an analysis of current and recently developed assessment techniques, including novel imaging and electrophysiological approaches used to study corticomotoneuronal pathology in ALS.
UR - http://www.scopus.com/inward/record.url?scp=84968732919&partnerID=8YFLogxK
U2 - 10.1016/j.clinph.2016.04.025
DO - 10.1016/j.clinph.2016.04.025
M3 - Scientific review articles
C2 - 27291884
AN - SCOPUS:84968732919
SN - 1388-2457
VL - 127
SP - 2643
EP - 2660
JO - Clinical Neurophysiology
JF - Clinical Neurophysiology
IS - 7
ER -